dichlororibofuranosylbenzimidazole has been researched along with Sclerosis, Systemic in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reimer, G | 1 |
| Scheer, U | 1 |
| Peters, JM | 1 |
| Tan, EM | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and Sclerosis, Systemic
| Article | Year |
|---|---|
Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes.
Topics: Animals; Antigens, Nuclear; Autoantibodies; Autoantigens; Cell Cycle; Cell Nucleolus; Dactinomycin; | 1986 |